Literature DB >> 17548905

Complicated parapneumonic effusion and empyema thoracis: microbiology and predictors of adverse outcomes.

K Y Tsang1, W S Leung, Veronica L Chan, Alsa W L Lin, C M Chu.   

Abstract

OBJECTIVES: To describe the microbiological characteristics of a cohort of patients with complicated parapneumonic effusion and empyema thoracis, and to identify the potential risk factors for adverse outcomes, with particular reference to the choice of empirical antibiotics, intrapleural fibrinolytics, adherence to management guidelines, and input from pulmonologists.
DESIGN: Retrospective review.
SETTING: Regional hospital, Hong Kong. PATIENTS: All patients with a diagnosis of complicated parapneumonic effusion/empyema thoracis admitted between January 2003 and June 2005. MAIN OUTCOME MEASURES: Microbiological characteristics, mortality, and surgery-free survival. RESULTS. There were 63 patients, with a mean age of 64 (standard deviation, 16) years and a male-to-female ratio of 45:18. The pleural fluid culture positivity rate was 68%; Streptococcus milleri (19%), Bacteroides (14%), Klebsiella pneumoniae (12%), and Peptostreptococcus (7%) were the most common organisms. Thirteen (21%) patients died during their index admission. Use of intrapleural fibrinolytics according to the guideline was associated with survival (P=0.001) while discordant initial antibiotic use was associated with mortality (P=0.002). Discordant initial antibiotic use was also independently associated with reduced surgery-free survival (P<0.001). Subgroup analysis showed that early intrapleural fibrinolytic use (within 4 days of diagnosis) was associated with decreased mortality (P<0.001), increased surgery-free survival (P=0.005), and shorter hospital stay (P=0.039).
CONCLUSION: Organisms identified from complicated parapneumonic effusion and empyema thoracis differ from those giving rise to community-acquired pneumonia. In these patients, adherence to guidelines, early concordant antibiotic treatment, intrapleural fibrinolytics, and input from a pulmonologist were associated with improved outcomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17548905

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  11 in total

1.  Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema.

Authors:  Emile S Altmann; Iain Crossingham; Stephen Wilson; Huw R Davies
Journal:  Cochrane Database Syst Rev       Date:  2019-10-30

2.  Loculated Empyema and SARS-CoV-2 Infection: A Report of Two Cases and Review of the Literature.

Authors:  Sarah Ayad; Kirolos Gergis; Sherif Elkattawy; Noreen Mirza; Basel Abdelazeem; Latika Patel; Carlos Remolina
Journal:  Eur J Case Rep Intern Med       Date:  2021-07-15

3.  Empyema thoracis.

Authors:  Ala Eldin H Ahmed; Tariq E Yacoub
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2010-06-17

4.  Complicated parapneumonic effusion and empyema: pleural decortication and video-assisted thoracic surgery.

Authors:  Shi-Ping Luh; Gwo-Jong Hsu; Chen Cheng-Ren
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

5.  Klebsiella pneumoniae related community-acquired acute lower respiratory infections in Cambodia: clinical characteristics and treatment.

Authors:  Blandine Rammaert; Sophie Goyet; Julien Beauté; Sopheak Hem; Vantha Te; Patrich Lorn Try; Charles Mayaud; Laurence Borand; Philippe Buchy; Bertrand Guillard; Sirenda Vong
Journal:  BMC Infect Dis       Date:  2012-01-10       Impact factor: 3.090

6.  Contemporary empyema thoracis necessitans in an adult male caused by Staphylococcus aureus: decortication is superior to traditional under water seal intercostal tube in chronic empyema.

Authors:  Liaqat Ali Chaudhry; Ahmed A Ba Mousa; Marwan Zamzami; Asirvatham Alwin Robert
Journal:  Pan Afr Med J       Date:  2015-02-09

7.  Clinical, Laboratory and Radiographic Features of Patients with Pneumonia and Parapneumonic Effusions.

Authors:  Sanja Petrusevska-Marinkovic; Irena Kondova-Topuzovska; Zvonko Milenkovic; Goran Kondov; Ankica Anastasovska
Journal:  Open Access Maced J Med Sci       Date:  2016-08-23

8.  A systematic review of comorbidities and outcomes of adult patients with pleural infection.

Authors:  Tamsin N Cargill; Maged Hassan; John P Corcoran; Elinor Harriss; Rachelle Asciak; Rachel M Mercer; David J McCracken; Eihab O Bedawi; Najib M Rahman
Journal:  Eur Respir J       Date:  2019-10-01       Impact factor: 16.671

Review 9.  Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breed.

Authors:  Alyssa S Shon; Rajinder P S Bajwa; Thomas A Russo
Journal:  Virulence       Date:  2013-01-09       Impact factor: 5.882

10.  Microbiological Characteristics and Predictive Factors for Mortality in Pleural Infection: A Single-Center Cohort Study in Korea.

Authors:  Cheol-Kyu Park; Hyoung-Joo Oh; Ha-Young Choi; Hong-Joon Shin; Jung Hwan Lim; In-Jae Oh; Yu-Il Kim; Sung-Chul Lim; Young-Chul Kim; Yong-Soo Kwon
Journal:  PLoS One       Date:  2016-08-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.